(Q35185749)

7 August 2017

1 reference

title

Agents in clinical development for the treatment of chronic hepatitis B. (English)

1 reference

7 August 2017

1 reference

Anneke K Raney

1

1 reference

7 August 2017

Robert K Hamatake

series ordinal

2

1 reference

7 August 2017

Zhi Hong

series ordinal

3

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Expert Opinion on Investigational Drugs

7 August 2017

published in

1 reference

7 August 2017

volume

12

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

1281-1295

1 reference

Evolving therapies for the treatment of chronic hepatitis B virus infection

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

The replication cycle of hepatitis B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Hepatitis B virus replication: novel roles for virus-host interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Hepatitis B virus immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Mechanisms of action of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Prospects for active immunotherapies for hepatitis B virus chronic carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Current pharmacotherapy for hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Entecavir: a potent new antiviral drug for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

5'-Nor carbocyclic 5'-deoxy-5'-(isobutylthio)adenosine and a 2',3'-dideoxy-2',3'-didehydro derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1281

10.1517/13543784.12.8.1281

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference